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Introduction, epidemiology, and natural history
The majority of pediatric cancers likely reflect the inherent risks
associated with the complex process of normal development
rather than aberrant responses to external insults.
Epidemiologic data has not identified any consistent environ-
mental factors, including parental exposures to carcinogens,
which have been consistently linked to tumor predilection (Ross
and Swensen, 2000). It therefore seems likely that many pedi-
atric tumors may be an infrequent and unfortunate conse-
quence of normal growth and development gone awry (Figure
1). Nowhere is this concept more evident than in pediatric
embryonal malignancies—solid tumors arising from cellular
populations that have not completed the process of terminal dif-
ferentiation during fetal and/or postnatal development. While
many pediatric cancers are thought to arise from blastemal
cells, this review will focus on neuroblastoma, retinoblastoma,
nephroblastoma (Wilms’ tumor), and hepatoblastoma as exam-
ples of the unique biological and clinical features inherent to the
solid malignant neoplasms of childhood.
While the four major embryonal malignancies account for
only slightly less than 20% of cancer observed in children less
than 15 years of age (Ries et al., 1999), they are by far the most
common neoplasms detected during very early childhood. The
median age of diagnosis for the embryonal cancers ranges from
approximately 1.5–3 years of age (Table 1), and the majority of
cases are diagnosed before the 5th birthday. Congenital cases
are relatively frequent, especially for retinoblastoma and neu-
roblastoma, strongly suggesting that disruption of normal devel-
opmental processes are involved in tumor initiation.
The natural history of neuroblastoma highlights many of the
unique features and conundrums of pediatric embryonal malig-
nancies. On the one hand, neuroblastoma shows the highest
spontaneous tumor regression rate of all human malignancies.
There are patients in the first year of life with a special pattern of
disseminated disease (Stage 4S) that can be readily identified
and treated with observation alone despite rapid initial tumor
progression. On the other hand, approximately 50% of patients
are older children with disseminated disease and show relent-
less tumor progression. These tumors are frequently refractory
to conventional dose-intensive therapies (despite initial
responses), and overall survival
remains less than 40% (Matthay et al.,
1999). Although 90% of cases are
diagnosed before age 5, neuroblas-
toma does occur in older children, and
very rarely adults, where it typically
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Figure 1. Putative oncogenic mechanisms of
pediatric embryonal and adult epithelial
tumors
Embryonal tumors presumably originate from
stem cell populations in organs and struc-
tures that are undergoing large-scale cell
division and differentiation as part of normal
growth and developmental (broad arrow).
Infrequent errors occur that could involve
alterations in chromatin structure or discrete
genomic mutations (thin arrows). In some
cases, these errors directly confer a growth
advantage to cells (dashed arrow) or predis-
pose cells to accumulate additional muta-
tions that eventually lead to tumor
formation. Adult epithelial tumors arise from
stem cell populations that normally function
in mature organs as a replacement source
for those cells constantly lost as a part normal
steady state physiology. Exposure to external
stimuli and/or de novo genomic mutation
results in expansion of this stem cell popula-
tion. This increases the risk of incurring addi-
tional mutations and a resultant malignant
clonal outgrowth. Germline alterations in
cancer predisposition genes provide a short-
cut to malignancy in both cases.
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follows a more indolent course but ultimately is fatal (Franks et
al., 1997). These clinical data suggest that there is a narrow
window of opportunity to accumulate the required genomic
alterations in susceptible committed, but not fully differentiated,
blastemal cells. The fact that forced MYCN expression to the
murine peripheral neural crest causes neuroblastomas at high
penetrance, but only within the first several months of life, rein-
forces the concept of a vulnerable time period prior to terminal
differentiation (Weiss et al., 1997).
Genetics
Genetic predisposition
Retinoblastoma provides the paradigm for heritable predisposi-
tion to cancer segregating as a dominant trait. Knudson’s math-
ematical prediction that retinoblastomas arise due to two
separate mutational events (Knudson, 1971) was validated by
the discovery of germline heterozygous mutations in RB1 with
somatically acquired inactivation of the other allele. Although
some exceptions do occur, RB1 germline mutations are typical-
ly highly penetrant, suggesting that even a single genomic hit is
sufficient to initiate the oncogenic process. However, additional
mutations are usually necessary for tumor formation.
Essentially all retinoblastomas show multiple other karyotypic
alterations, including gain of 1q and 6p, loss of 16q, and high
level amplification of the MYCN protooncogene (Chen et al.,
2001). Thus, even the most straightforward pediatric embryonal
cancer shows genomic alterations that suggest that establish-
ment of a fully malignant phenotype requires multiple somatical-
ly acquired alterations. It remains a complete mystery as to why
germline mutations in RB1 result in strict tissue specificity (reti-
na and bone) for neoplasia, yet acquired inactivation of RB1 is
an essential step toward the malignant phenotype in multiple
human cancers (Hanahan and Weinberg, 2000).
Heritable susceptibilities in the other embryonal cancers
appear more complex. The WT1 tumor suppressor gene is
mutated in about 10% of sporadic Wilms’ tumors, but germline
mutations in this gene are rare.There are at least two other pre-
disposition loci at 17q12-21 (FWT1) and 19q13 (FWT2) and
probably others (Huff et al., 1997). Familial neuroblastoma is
also likely to be genetically heterogeneous, but a major predis-
position gene has been mapped to 16p12-13 (Maris et al.,
2002). Hepatoblastomas have only very rarely been reported in
siblings, but heritable predisposition does occur in patients with
germline mutations of the adenomatous polyposis coli (APC)
gene (Giardiello et al., 1996). Constitutional chromosomal
abnormalities and associated congenital anomalies are rare in
patients with embryonal cancers, but these unique patients
have directly contributed to the discoveries of RB1 and WT1
and may be important for gene identification in other pediatric
cancers (Table 1).
Somatically acquired genomic alterations
Despite the generally held notion that embryonal cancers are
simpler from a genetic standpoint than adult neoplasms, these
cancers show multiple chromosomal rearrangements, suggest-
ing a complicated series of acquired alterations during malig-
nant evolution.This is best exemplified in neuroblastoma, where
20%–25% of cases harbor multiple copies of the MYCN gene
with concomitant overexpression of the mRNA and protein.This
mutation has a profound effect on tumor clinical behavior. In
addition, metastatic neuroblastomas are generally diploid (or
near tetraploid) and show structural rearrangements, including
loss of heterozygosity (LOH) at 1p36, 3p14-25, 11q14-23 and
14q32, as well as unbalanced gain of 17q23-25 (Maris and
Brodeur, 2001). This suggests that there can be additional bio-
logically relevant genetic hits in neuroblastoma, though the
involved genes remain to be elucidated.
Secondary genetic hits in other embryonal tumors are less
well defined. Activating mutations in CTTNB1 (β-catenin) are
frequent in both hepatoblastomas and Wilms’ tumors (Koch et
al., 1999; Koesters et al., 1999). In addition, there are multiple
regions of the genome that are commonly and recurrently delet-
ed in each of the embryonal cancers, and epigenetic events
may play an important role in functional inactivation of putative
suppressor genes at these loci. TP53 mutations, which are a
common finding in many adult cancers, are not common initially
in embryonic tumors, but acquired mutations do occur under the
selective pressure of chemotherapy and may contribute to treat-
ment failures (Keshelava et al., 2001).
Conventional therapeutics
Like all human malignancies, the major variable affecting treat-
ment planning is anatomic extent of disease. Age at diagnosis is
another important variable, both in terms of age being a surro-
gate marker for disease aggressiveness and likelihood for mor-
bidity to cytotoxic therapy.There has been a recent trend toward
combining these clinical features with tumor-specific biological
Table 1. Clinical and genetic features of embryonal malignancies
Median age Overall Predisposition 
Tumor Incidence1 diagnosis (months) Associated conditions survival3 genes/loci4
Neuroblastoma 9.1 17 Hirschsprung disease 64% HNB1 (16p12-13)
Central hypoventilation 1p36.3
11q14-23




Retinoblastoma 4.0 24 13q deletion syndrome 94% RB1 (13q14)
Hepatoblastoma 1.3 16 FAP 59% APC (5q22)
Beckwith-Wiedemann
1Average age-adjusted annual incidence rate per million children < 15 years of age (Ries et al., 1999).
2WAGR: Wilms’ tumor, aniridia, genitourinary anomalies, and mental retardation syndrome.
3Five-year relative survival rates estimated between 1985–1994 (Ries et al., 1999).
4Constitutional heterozygous alterations at these loci predispose to neoplasm. HNB1, FWT1, and FWT2 are postulated genes at regions identified by genetic
linkage analysis. 1p36.3 and 11q14-23 are sites of constitutional deletions identified in patients with multifocal neuroblastoma.
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prognostic markers in order to stratify patients into risk groups.
This is perhaps best formulated in neuroblastoma, where the
tumor biological features of MYCN amplification and DNA index
(ploidy) are independently prognostic for disease outcome and
are used clinically to assign treatment intensity. Other somati-
cally acquired genomic alterations, such as 1p36 LOH and/or
unbalanced gain of 17q23-25, might add further precision to the
current risk stratification scheme. Future Wilms’ tumor coopera-
tive group trials will stratify therapy based on 1p and 16q LOH
status.
The embryonal cancers can be exquisitely chemo- and radi-
ation-therapy responsive. Overall survival rates continue to
improve, and for retinoblastoma and Wilms’ tumor have
approached the point where cure is the expectation (Table 1).
Even the most aggressive neuroblastomas with MYCN amplifi-
cation typically show good initial responses to cytotoxic therapy.
The vast majority of patients with localized neuroblastoma can
be cured with surgery alone, and most hepatoblastomas and
“intermediate risk” neuroblastomas can be cured with relatively
modest neoadjuvant chemotherapy. For these cancers, current
emphasis is on therapy reduction in order to avoid late morbidi-
ty. However, survival rates for metastatic neuroblastoma remain
suboptimal (3-year EFS 30%),despite escalating chemotherapy
intensity to the point of using myeloablative chemotherapy with
autologous, purged bone marrow rescue (Matthay et al., 1999).
Novel treatment approaches
The distinctive oncogenic mechanisms present in embryonal
malignancies suggest that their inherent physiologic state and
protein expression profile are quite different than host somatic
tissues. Such proteins and pathways could provide attractive
targets for novel treatment strategies (Figure 2). For example,
recognition of the adrenergic phenotype of neuroblastomas has
led to the development of metaiodobenzylguanidine (MIBG) as
both a diagnostic and therapeutic agent. Targeted radiotherapy
with 131I labeled MIBG has shown extraordinary responses in
highly refractory disease, even in tumors that have progressed
following myeloablative chemotherapy, with minimal non-
hematopoietic toxicity (Matthay et al., 1998). The observation
that TrkB is preferentially expressed in metastatic neuroblas-
toma suggests that the neurotrophin signaling pathway might
also provide a relatively specific target.Targeted inhibition of Trk
receptors tyrosine kinase activity showed a significant growth
inhibitory effect on several human-derived neuroblastoma
xenografts and efficacy was related to TrkB expression level
(Evans et al., 1999).
Intervention through transcriptional modulation is another
therapeutic venue in embryonal malignancies. MYCN provides
an obvious target for the subset of neuroblastomas (and
retinoblastomas) with genomic amplification, but attempts to
exploit this with antisense or other targeted approaches have
been fraught with difficulties. Interfering with the mechanisms
allowing for escape from apoptosis is appealing, especially in
MYCN amplified cells where the oncogene itself provides a
powerful apoptotic stimuli that must be circumvented. Antisense
oligonucleotides to BCL2 are currently in clinical trials, and
demethylating agents (e.g., decitabine) are being considered
following the observation that MYCN amplification is often asso-
ciated with loss of caspase 8 expression due to promoter site
hypermethylation (Teitz et al., 2000). Based on their ability to
induce differentiation in tissue culture systems, retinoids have
had a positive clinical impact in neuroblastoma. Encouraging
results from a randomized trial of 13-cis-retinoic acid (Matthay
et al., 1999) has fueled efforts to define retinoic acid isomers
that promote maximum tumor differentiation (or kill) without
excess toxicity (Reynolds, 2000).
Novel immunotherapeutic strategies targeting neuroblas-
toma cell surface structures have received significant attention
in neuroblastoma. The disialoganglioside GD2 is highly
expressed on the cell surface of virtually all neuroblastoma
cells, while being present on only a restricted range of normal
tissues, including peripheral nerves. Monoclonal antibodies
against GD2 show clinical activity, and antibody-dependent
cytotoxicity can be enhanced with concomitant administration of
cytokines (Ozkaynak et al., 2000). An anti-GD2 monoclonal
antibody combined in alternating cycles with GM-CSF or IL2 is
currently being studied in a randomized trial on the backbone of
13-cis-retinoic acid for neuroblastoma patients in first complete
or very good partial response. A variety of other immunothera-
peutic approaches are also currently under investigation,
including vaccines (cytokine transfected autologous tumor cells,
dendritic cell, anti-idiotype), anti-GD2-cytokine fusion antibod-
ies, and ex vivo T cell augmentation.
Finally, efforts to modulate the extracellular environment are
being pursued. Antiangiogenic strategies hold promise for pedi-
atric solid cancers, especially neuroblastoma, where high-risk
disease features are correlated with primary tumor vascularity
(Meitar et al., 1996). It seems likely that process of new vessel
formation in embryonal malignancies may involve both vasculo-
genesis (de novo assembly of endothelial precursor cells) and
angiogenesis (recruitment of angiogenic sprouts from the exist-
ing vasculature), which may predict for differential sensitivity to
antiangiogenic strategies being explored in adult neoplasms.
Antiangiogenic strategies have shown promise in preclinical
Figure 2. Novel therapeutic strategies in neuroblastoma
A subset of the most promising new therapeutic approaches currently in
clinical trials or in late preclinical development.
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models of neuroblastoma and Wilms’ tumor (Kim et al., 2001).
Current preclinical studies are focused on combination strate-
gies with conventional or low-dose cytotoxic chemotherapy
(Klement et al., 2000). The unique problem of defining exactly
how to use neovascular inhibition strategies in growing children
has not yet been addressed, as protracted chronic inhibition
schedules to sustain tumor dormancy are unlikely to be useful
in the pediatric population.
Challenges for the future
Perhaps because they reflect corrupted normal developmental
pathways, embryonal tumors have provided a fruitful area of
basic science research, including discoveries of many of the
paradigms of modern cancer genetics. A striking observation is
that in spite of shared basic oncogenic mechanisms with adult
cancers, pediatric embryonic tumors are virtually never seen
after the first decade of life. This could reflect biological differ-
ences in respective stem cell populations that are targeted in
adult versus pediatric malignancies. The specificity of genetic
mutation is also likely to play a key role. Finally, the differences
in cellular growth environments between developing pediatric
and mature adult host tissues may favor certain types of cancer
over others. Future studies in pediatric embryonic tumors will
address these issues and provide an invaluable opportunity
toward better understanding of both normal and abnormal
human growth and development.
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